Signature-based analysis of MET proto-oncogene mutations using DHPLC

被引:11
|
作者
Nickerson, ML
Weirich, G
Zbar, B
Schmidt, LS
机构
[1] NCI, Immunobiol Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA
[2] NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA
关键词
DHPLC; MET proto-oncogene; mutation detection; pedigree analysis; single nucleotide polymorphism; SNP;
D O I
10.1002/1098-1004(200007)16:1<68::AID-HUMU12>3.0.CO;2-U
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Research tools which improve mutation detection, SNP discovery, and allele characterization will facilitate studies of cancer, inherited disease, and genomic evolution. Denaturing High-Performance Liquid Chromatography (DHPLC) is a recently developed methodology for detection of heteroduplexes formed in DNA samples containing mismatches between wild type and mutant strands. In an effort to develop a rapid, sensitive mutation detection method for studies of families with inherited kidney cancer, we evaluated DHPLC for detection and analysis of MET protooncogene mutations in papillary renal carcinomas (PRC), We found DHPLC to be 100% accurate in detecting 15 known disease-associated MET mutations. Significantly, each MET mutation and two novel SNPs generated a characteristic chromatographic profile or signature with reproducible distinguishing features. Standardization of DHPLC reagents and improved methods design were critical to the reliability and accuracy of mutation prediction. Improvements included addition of a 75% acetonitrile wash followed by a rejuvenating gradient, and detailed analysis of signature shape, retention time (RT), RT differences (Delta RT), and temperature-dependent (melt) profiling, We used signatures to predict mutations in new PRC samples, mutation carriers in asymptomatic hereditary PRC family members, and in a blind study of previously characterized DNAs. Application to SNP discovery is discussed, Hum Mutat 16:68-76, 2000, Published 2000 (C) Wiley-Liss, Inc.(dagger)
引用
收藏
页码:68 / 76
页数:9
相关论文
共 50 条
  • [31] Prevalence of RET proto-oncogene mutations in medullary thyroid carcinoma
    Gregg, JP
    Chang, AS
    Yamane, AJ
    Grody, WW
    AMERICAN JOURNAL OF PATHOLOGY, 1996, 149 (05): : ST13 - ST13
  • [32] RET proto-oncogene mutations in thyroid carcinomas: Clinical relevance
    Pacini, F
    Elisei, R
    Romei, C
    Pinchera, A
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2000, 23 (05) : 328 - 338
  • [33] Hepatoblastoma in an adult associated with c-met proto-oncogene imbalance
    Kuniyasu, H
    Yasui, W
    Shimamoto, F
    Fujii, K
    Nakahara, M
    Asahara, T
    Dohi, K
    Tahara, E
    PATHOLOGY INTERNATIONAL, 1996, 46 (12) : 1005 - 1010
  • [34] RET proto-oncogene mutations in thyroid carcinomas: Clinical relevance
    F. Pacini
    R. Elisei
    C. Romei
    A. Pinchera
    Journal of Endocrinological Investigation, 2000, 23 : 328 - 338
  • [35] Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene
    Schmidt, L
    Junker, K
    Weirich, G
    Glenn, G
    Choyke, P
    Lubensky, I
    Zhuang, ZP
    Jeffers, M
    Woude, GV
    Neumann, H
    McClellan, W
    Linehan, WM
    Zbar, B
    CANCER RESEARCH, 1998, 58 (08) : 1719 - 1722
  • [36] THE P53 PROTO-ONCOGENE CAN SUPPRESS TRANSFORMATION BY OTHER ONCOGENES, AND MUTATIONS IN THE PROTO-ONCOGENE CAN ACTIVATE THE GENE FOR TRANSFORMATION
    HINDS, PW
    FINLAY, CA
    LEVINE, AJ
    COMMON MECHANISMS OF TRANSFORMATION BY SMALL DNA TUMOR VIRUSES, 1989, : 83 - 101
  • [37] Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: Modeling studies
    Miller, M
    Ginalski, K
    Lesyng, B
    Nakaigawa, N
    Schmidt, L
    Zbar, B
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2001, 44 (01) : 32 - 43
  • [38] Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas
    Ferracini, R
    Olivero, M
    DiRenzo, MF
    Martano, M
    DeGiovanni, C
    Nanni, P
    Basso, G
    Scotlandi, K
    Lollini, PL
    Comoglio, PM
    ONCOGENE, 1996, 12 (08) : 1697 - 1705
  • [39] Association of Genetic Variation in the MET Proto-Oncogene With Schizophrenia and General Cognitive Ability
    Burdick, Katherine E.
    DeRosse, Pamela
    Kane, John M.
    Lencz, Todd
    Malhotra, Anil K.
    AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (04): : 436 - 443
  • [40] Candidate Gene Studies in the GWAS Era: The MET Proto-Oncogene, Neurocognition, and Schizophrenia
    Cannon, Tyrone D.
    AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (04): : 369 - 372